Altimmune shares last traded at $5.6750, with a volume of 4,605,667 shares changing hands. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after purchasing an additional 5,253 shares during the period. Kingswood Wealth Advisors LLC acquired a new stake in shares of Altimmune during the second quarter worth about $40,000.